Current concepts in the therapy of the spondyloarthritides

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Xenofon Baraliakos, Juergen Braun

Abstract

Recent success in the treatment of patients with the more severe forms of spondyloarthritides (SpA) has dramatically changed old paradigms. There is evidence that anti-tumor necrosis factor (TNF)-alpha therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis. Based on recent data on more than 1000 patients with AS and psoriatic arthritis, this treatment seems to be even more effective than in rheumatoid arthritis (RA). The currently available anti-TNFalpha agents, infliximab, etanercept, and adalimumab, are approved for the treatment of RA in the US and in Europe. TNFalpha blockers may even be considered as a first-line treatment in patients with active AS whose condition is not sufficiently controlled with NSAIDs, as in the case of axial disease. There is preliminary evidence that both agents also work in other SpA, such as undifferentiated SpA. There is hope that ankylosis may be preventable, but it remains to be shown whether patients benefit from long-term anti-TNFalpha therapy and whether radiologic progression and ankylosis can be stopped. Furthermore, it seems that anti-TNFalpha therapy can also improve clinical manifestations of other inflammatory spinal disorders, such as sc...Continue Reading

References

Aug 11, 1992·Journal of Neuroimmunology·M R WellsU Vaidya
Dec 17, 1991·European Journal of Pharmacology·R M BluthéK W Kelley
Apr 1, 1988·Annals of Neurology·K W Selmaj, C S Raine
Jul 1, 1996·Current Opinion in Rheumatology·J Braun, J Sieper
Feb 20, 1997·Nature·T Kurahashi, A Menini
Jan 20, 1998·Arthritis and Rheumatism·J BraunJ Sieper
Sep 3, 1998·Seminars in Arthritis and Rheumatism·P GoupilleA J Freemont
Jan 19, 1999·Rheumatic Diseases Clinics of North America·M Leirisalo-Repo
Oct 16, 1999·Annals of Internal Medicine·P H BrionK C Kalunian
Feb 26, 2000·Arthritis Care and Research : the Official Journal of the Arthritis Health Professions Association·M M Ward
Apr 9, 2001·The New England Journal of Medicine·F J Fernández-Fernández, P Sesma
Oct 13, 2001·The New England Journal of Medicine·J KeaneM M Braun
Jan 5, 2002·Annals of the Rheumatic Diseases·G BurbageK Lim
Mar 5, 2002·Annals of the Rheumatic Diseases·I OlivieriF Cantini
Apr 2, 2002·The Journal of Bone and Joint Surgery. British Volume·J G BurkeJ M Fitzpatrick
May 3, 2002·The New England Journal of Medicine·Jennifer D GormanJohn C Davis
Jul 19, 2002·Arthritis and Rheumatism·Annette D WagnerHenning Zeidler
Aug 7, 2002·Spine·Yoshihito AokiKjell Olmarker
Aug 15, 2002·Annals of the Rheumatic Diseases·F SoliotisA S M Jawad
Nov 7, 2002·International Journal of Cardiology·Stefan D Anker, Andrew J S Coats

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.